Rational Design of Oral Modified-Release Drug Delivery Systems

Developing Solid Oral Dosage Forms

Volumn , Issue , 2009, Pages 469-499

  Qiu, Yihong ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882902320     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-53242-8.00020-5     Document Type: Chapter

References (138)

1. Qiu Y., Zhang G. Research and Development Aspects of Oral Controlled Release Systems. Handbook of Pharmaceutical Controlled Release Technology 2000, 465-503. Marcel Dekker, Inc., New York, NY. D.L. Wise, A.M. Klibanov, R. Langer, A.G. Mikos, N.A. Peppas, D.J. Trantolo, G.E. Wnek, M.J. Yaszeski (Eds.).
2. Qiu, Y. (2007). Design and Evaluation of Oral Modified-Release Dosage Forms Based on Drug Property and Delivery Technology. Proc. CAE/AAPS/CPA/CRS/FIP/APSTJ Conference: Oral Controlled Release Development and Technology. Shanghai, pp. 34-43.
3. Getsios D., Caro J.J., Ishak K.J., El-Hadi W., Payne K., O'Connel M., Albrecht D., Feng W., Dubois D. Oxybutynin extended release and tolterodine immediate release. Clin. Drug Invest. 2004, 24(2):81-88.
4. Guidance for Industry. (1997). SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In vitro Dissolution Testing and In vivo Bioequivalence Documentation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
5. Wise, D.L., Klibanov, A.M., Langer, R., Mikos, A.G., Peppas, N.A., Trantolo, D.J. Wnek, G.E. & Yaszeski, M.J. (eds). Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker, Inc., New York, NY.
6. Controlled Drug Delivery: Fundamentals and Applications 1987, Marcel Dekker, Inc., New York, NY. 2nd edn. J.R. Robinson, V.H.L. Lee (Eds.).
7. Kydonieus, A. (1980). Fundamental Concepts of Controlled Release. In: Controlled Release Technologies: Methods, Theory, and Applications, A.F. Kydonieus (ed.), Vol. 1, p. 7.
8. Narasimhan B. Accurate Models in Controlled Drug Delivery Systems. Handbook of Pharmaceutical Controlled Release Technology 2000, 155-181. Marcel Dekker, Inc., New York, NY. D.L. Wise, A.M. Klibanov, R. Langer, A.G. Mikos, N.A. Peppas, D.J. Trantolo, G.E. Wnek, M.J. Yaszeski (Eds.).
9. Colombo P., Santi P., Bettini R., Brazel C.S. Drug Release from Swelling-Controlled Systems. Handbook of Pharmaceutical Controlled Release Technology 2000, 183-209. Marcel Dekker, Inc., New York, NY. D.L. Wise, A.M. Klibanov, R. Langer, A.G. Mikos, N.A. Peppas, D.J. Trantolo, G.E. Wnek, M.J. Yaszeski (Eds.).
10. Ford J.L., Rubinstein M.H., McCaul F., Hogan J.E., Edgar P.J. Importance of drug type, tablet shape and added diluents on drug release kinetics from hydroxypropylmethylcellulose matrix tablets. Int. J. Pharm. 1987, 40:223-234.
11. Lee P.I. Dimensional changes during drug release from a glassy hydrogel matrix. Polymer 1983, 24(Communications):45-47.
12. Lee P.I., Peppas N.A. Prediction of polymer dissolution in swellable controlled release systems. J. Controlled Release 1987, 6:207-215.
13. Lee P.I. Kinetics of drug release from hydrogel matrices. J. Controlled Release 1985, 2:277-288.
14. Lee P.I. Controlled drug release from polymeric matrices involving moving boundaries. Controlled Release of Pesticides and Pharmaceuticals 1981, 39-48. Plenum Publishing, New York, NY. D. Lewis (Ed.).
15. Lee P.I. Diffusional release of a solute from a polymeric matrix-approximate analytical solutions. J. Membr. Sci. 1980, 7:255-275.
16. Peppas N.A. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta Helv. 1985, 60:110-111.
17. Ford J.L., Mitchell K., Rowe P., Armstrong D.J., Elliott P.N.C., Rostron C., Hogan J.E. Mathematical modeling of drug release from hydroxypropyl-methylcellulose matrices: Effect of temperature. Int. J. Pharm. 1986, 71:95-104.
18. Baveja S.K., Ranga Rao K.V. Sustained release tablet formulation of centperazine. Int. J. Pharm. 1986, 31:169-174.
19. Peppas N.A., Sahlin J.J. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int. J. Pharm. 1989, 57:169-172.
20. Ranga Rao, K.V., Padmalatha D.K. & Buri, P. Influence of molecular size and water solubility of the solute on its release from swelling and erosion controlled polymeric matrices. J. Controlled Release, 12, 133-141.
21. Harland R.S., Gazzaniga A., Sangalli M.E., Colombo P., Peppas N.A. Drug/polymer matrix swelling and dissolution. Pharm. Res. 1988, 5:488-494.
22. Catellani P., Vaona G., Plazzi P., Colombo P. Compressed matrices, formulation and drug release kinetics. Acta Pharm. Technol. 1988, 34:38-41.
23. Lee P.I., Kim C.J. Effect of geometry on swelling front penetration in glassy polymers. J. Membrane Science 1992, 65:77-92.
24. Lee P.I., Kim C.J. Probing the mechanisms of drug release from hydrogels. J. Controlled Release 1991, 16:229-236.
25. Ju R.T., Nixon P.R., Patel M.V., Tong D.M. Drug release from hydrophilic matrices. 2. A mathematical model based on the polymer disentanglement concentration and the diffusion layer. J. Pharm. Sci. 1995, 84(12):1464-1477.
26. Ju R.T., Nixon P.R., Patel M.V. Drug release from hydrophilic matrices. 1. New scaling laws for predicting polymer and drug release based on the polymer disentanglement concentration and the diffusion layer. J. Pharm. Sci. 1995, 84(12):1455-1463. Dec.
27. Liu P., Ju T.R., Qiu Y. Diffusion-Controlled Drug Delivery Systems in Design of Controlled Drug Delivery Systems, 2006, 107-137. X. Li & B.R. JasdiMcGraw-Hill Companies Inc. P. Liu, T.R. Ju (Eds.).
28. Lee, P. I. (2007). Evolution of oral controlled/modified release dosage forms. Proc. CAE/AAPS/CPA/CRS/FIP/APSTJ Conference, Oral Controlled Release Development and Technology. Shanghai, pp. 22-31.
29. Recipes for Fifty-Two Ailment, Mawangdui Medical Manuscript. Dated 168 BC.
30. (281-341) Handbook of prescriptions for Urgent Cares.
31. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci. 1961, 50:847.
32. Higuchi T. Mechanism of sustained release medication, theoretical analysisof rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 1963, 52:1145.
33. Martin A., Bustamante P., Chun A.H.C. Physical Pharmacy 1993, Lea & Febiger, Malvern, PA, pp. 324-355. 4th edn.
34. Crank J. Diffusion in Heterogeneous Media. The Mathematics of Diffusion 1986, 266-285. Clarendon Press, Oxford. 2nd edn. J. Crank (Ed.).
35. Ritger P.L., Peppas N.A. A simple equation for description of solute Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or disk. J. Controlled Release 1987, 5:23-26.
36. Zhou Y., Chu J.S., Zhou T., Wu X.Y. Modeling of drug release from two-dimensional matrix tablets with anisotropic properties. Biomaterials 2004, 26:945-952.
37. Wu X.Y., Zhou Y. Studies of diffusional release of a dispersed solute from polymeric matrixes by finite element method. J. Pharm. Sci. 2000, 88(10):1050-1057.
38. Zhou Y., Wu X.Y. Finite element analysis of diffusional drug release from complex matrix systems. I. Complex geometries and composite structures. J. Control. Rel. 1997, 49:277-288.
39. Zhou Y., Wu X.Y. Finite element analysis of diffusional drug release from complex matrix systems. II. Factors influencing release kinetics. J. Control. Rel. 1998, 51:57-72.
40. Yonezawa Y., Ishida S., Suzuki S., Sunada H. Release from or through a wax matrix system. I. Basic release properties of the wax matrix system. Chem. Pharm. Bull. 2001, 49(11):1448-1451.
41. Yonezawa Y., Ishida S., Sunada H. Release from or through a wax matrix system. V. Applicability of the square-root time law equation for release from a wax matrix tablet. Chem. Pharm. Bull. 2003, 51(8):904-908.
42. Yonezawa Y., Ishida S., Sunada H. Release from or through a wax matrix system. VI. Analysis and prediction of the entire release process of the wax matrix tablet. Chem. Pharm. Bull. 2005, 53(8):915-918.
43. Hildgen P., McMullen J. A new gradient matrix, formulation and characterization. J. Contr. Rel. 1995, 34:263-271.
44. Kim C. Compressed donut-shaped tablets with zero-order release kinetics. Pharm. Res. 1995, 12:1045-1048.
45. Benkorah A., McMullen J. Biconcave coated, centrally perforated tablets for oral controlled drug delivery. J. Contr. Rel. 1994, 32:155-160.
46. Conte U., Maggi L., Colombo P., Manna A. Multi-layered hydrophilic matrices as constant release devices (Geomatrix™ Systems). J. Contr. Rel. 1993, 26:39-47.
47. Scott D., Hollenbeck R. Design and manufacture of a zero-order sustained-release pellet dosage form through nonuniform drug distribution in a diffusional matrix. Pharm. Res. 1991, 8:156-161.
48. Brooke D., Washkuhn R. Zero-order drug delivery system, Theory and preliminary testing. J. Pharm. Sci. 1977, 66:159-162.
49. Lipper R., Higuchi W. Analysis of theoretical behavior of a proposed zero-order drug delivery system. J. Pharm. Sci. 1977, 66:163-164.
50. Hsieh D., Rhine W., Langer R. Zero-order controlled release polymer matrices for micro and macro-molecules. J. Pharm. Sci. 1983, 72:17-22.
51. Lee I.P. Novel approach to zero-order drug delivery via immobilized nonuniform drug distribution in glassy hydrogels. J. Pharm. Sci. 1984, 70:1344-1347.
52. Lee I.P. Effect of non-uniform initial drug concentration distribution on the kinetics of drug release from glassy hydrogel matrices. Polymer 1984, 25:973-978.
53. Kuu W.-Y., Yalkowsky S.H. Multiple-hole approach to zero-order release. Journal of Pharmaceutical Sciences 1985, 74(9):926-933.
54. Kim C. Controlled release from triple layer, donut-shaped tablets with enteric polymers. AAPS Pharm Sci Tech. 2005, 6(3):E429-E436.
55. Bajpai S.K., Bajpai M., Saxena S., Dubey S. Quantitative interpretation of the deviation from "zero-order" kinetics for the release of cyanocobalamin from a starch-based enzymatically degradable hydrogel. Journal of Macromolecular Science, Part A, Pure and Applied Chemistry 2006, 43(8):1273-1277.
56. Wang C.-C., Tejwani (Motwani) M.R., Roach W.J., Kay J.L., Yoo J., Surprenant H.L., Monkhouse D.C., Pryor T.J. Development of near zero-order release dosage forms using three-dimensional printing (3-DP™). Technology, Drug Development and Industrial Pharmacy 2006, 32(3):367-376.
57. Kshirsagar, R., Joshi, M. & Raichandani, Y. Extended release formulation of levetiracetam. US Patent Application # 20060165796.
58. Delargy A.M., Timmins P., Minhom C., Howard J.R. The optimization of a pH independent matrix for the controlled release of drug materials using in vitro modeling. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 1989, 16:378-379.
59. Ugarkovic S., Trendovska-Serafimovska G., Sapkareva B. Controlled release formulation of verapamil hydrochloride tablets. Acta. Pharma. 1996, 46:155-157.
60. Venkatramana R., Engh K., Qiu Y. Design of pH-independent controlled release matrix tablets for acidic drugs. Int. J. Pharm. 2000, 252(1-2):81-86.
61. Tatavarti A.S., Mehta K.A., Augsburger L.L., Hoag S.W. Influence of methacrylic and acrylic acid polymers on the release performance of weakly basic drugs from sustained release hydrophilic matrices. J. Pharm. Sci. 2004, 93(9):2319-2331.
62. Tatavarti A.S., Hoag S.W. Microenvironmental pH modulation based release enhancement of a weakly basic drug from hydrophilic matrices. J. Pharm. Sci. 2006, 95(7):1459-1468.
63. Howard, J.R., Timmins, P. (1988). Controlled Release Formulation, US Patent 4 792 452.
64. Zhang, G. & Pinnamaraju, P. (1997). Sustained Release Formulation Containing Three Different Types of Polymers, US Patent 5 695 781.
65. Qiu, Y., Rao, V. & Engh, K. pH-independent extended-release pharmaceutical formulation, US Patent 6 150 410.
66. Po L.W., et al. Characterization of commercially available theophylline sustained- or controlled-release systems, in-vitro drug release profiles. Int. J. Pharm. 1990, 66:111-130.
67. Pillay V., Fassihi R. A novel approach for constant rate delivery of highly soluble bioactives from a simple monolithic system. J. Contr. Rel. 2000, 67:67-78.
68. Hite M., Federici C., Turner S., Fassihi R. Novel design of a self-correcting monolithic controlled-release delivery system for tramadol. Drug Del. Tech. 2003, 3:48-55.
69. Rao V., Haslam J., Stella V. Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE)(7m)-beta-cyclodextrin as a solubilizing agent. J. Pharm. Sci. 2001, 90:807-816.
70. Tanaka, N., Imai, K., Okimoto, K., Ueda, S., Tokunaga, Y., Ohike, A., Ibuki, R., Higaki, K. & Kimura, T. (2005). Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine. J. Control Release, 58, 108(2-3), 386-395.
71. Shajahan A., Poddar S.S. A flexible technology for modified release of drugs, multi layered tablets. J. Controlled Release 2004, 97(3):393-405.
72. Qiu Y., Chidambaram N., Flood K. Design and evaluation of layered diffusional matrices for zero-order sustained-release. J. Controlled Release 1998, 51:123-130.
73. Qiu Y., Flood K., Marsh K., Carroll S., Trivedi J., Arneric S.P., Krill S.L. Design of sustained-release matrix systems for a highly water-soluble compound, ABT-089. Int. J. Pharm. 1997, 157:43-52.
74. Ozeki T., Yuasa H., Okada H. Controlled release of drug via methylcellulose-carboxyvinylpolymer interpolymer complex solid dispersion. AAPS PharmSciTech. 2005, 6(2):E231-E236.
75. Levina M., Rajabi-Siahboomi A.R. The influence of excipients on drug release from hydroxypropyl methylcellulose matrices. J. Pharm. Sci. 2004, 93(11):2746-2754.
76. Bajwa G.S., Hoebler K., Sammon C., Timmins P., Melia C.D. Microstructural imaging of early gel layer formation in HPMC matrices. J. Pharm. Sci. 2006, 95(10):2145-2157.
77. Kazarian S.G., van der Weerd J. Simultaneous FTIR spectroscopic imaging and visible photography to monitor tablet dissolution and drug release. Pharm. Res. 2008, 25(4):853-860.
78. Donbrow M., Friedman M. Enhancement of permeability of ethyl cellulose films for drug penetration. J. Pharm. Pharmacol. 1975, 27:633.
79. Donbrow M., Samuelov Y. Zero order drug delivery from double-layered porous films, release rate profiles from ethyl cellulose, hydroxypropyl cellulose and polyethylene glycol mixtures. J. Pharm. Pharmacol. 1980, 32:463.
80. Rowe R.C. The effect of the molecular weight of ethyl cellulose on the drug release properties of mixed films of ethyl cellulose and hydroxypropyl methylcellulose. Int. J. Pharm. 1986, 29:37-41.
81. Porter S., Ghebre-Sellassie I. Key factors in the development of modified-release pellets. Multiparticulate Oral Drug Delivery 1994, 217-284. Marcel Dekker, New York. I. Ghebre-Sellassie (Ed.).
82. Theeuwes, F. & Higuchi, T. (1975). US patent 3 916 899.
83. McClelland G.A., Sutton S.C., Engle K., Zentner G.M. The solubility-modulated osmotic pump, in vitro/in vivo release of diltiazem hydrochloride. Pharm Res. 1991, 8:88-92.
84. Makhija S.N., Vavia P.R. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane. J. Control Release 14, 2003, 89(1):5-18.
85. Prabakaran D., Singh P., Kanaujia P., Mishra V., Jaganathan K.S., Vyas S.P. Controlled porosity osmotic pumps of highly aqueous soluble drug containing hydrophilic polymers as release retardants. Pharm. Dev. Technol. 2004, 9(4):435-442.
86. Okimoto K., Tokunaga Y., Ibuki R., Irie T., Uekama K., Rajewski R.A., Stella V.J. Applicability of (SBE)7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs). Int. J. Pharm. 2004, 286(1-2):81-88.
87. Sotthivirat S., Haslam J.L., Stella V.J. Controlled porosity-osmotic pump pellets of a poorly water-soluble drug using sulfobutylether-cyclodextrin, (SBE)7M-CD, as a solubilizing and osmotic agent. J. Pharm. Sci. 2007, 96(9):2364-2374.
88. Anand V., Kandarapu R., Garg S. Ion-exchange resins, carrying drug delivery forward. Drug Discovery Today 2001, 6(17):905-914.
89. El-Menshawy M.E., Ismail A.A. Polysalt flocculates as a physicochemical approach in the development of controlled-release oral pharmaceuticals. Pharmazie 1976, 31(12):872-874.
90. Bonferoni M.C., Rossi S., Ferrari F., Caramella C. Development of oral controlled release tablet formulations based on diltiazem-carrageenan complex. Pharmaceutical Development and Technology 2004, 9(2):155-162.
91. Chaudhry N.C., Saunders L. Sustained release of drugs from ion exchange resins. J Pharm. Pharmacol. 1956, 38:975-986.
92. Chaubal, M.V. (2003). Synthetic polymer-based ion exchange resins, excipients and actives. Drug Delivery Technology 3(5).
93. Abdekhodaie M.J., Wu X.Y. Drug release from ion-exchange microspheres, mathematical modeling and experimental verification. Biomaterials 2008, 29:1654-1663.
94. Abdekhodaie M.J., Wu X.Y. Drug loading onto ion exchange microspheres, modeling study and experimental verification. Biomaterials 2006, 27:3652-3662.
95. Sriwongjanya M., Bodmeier R. Effect of ion exchange resins on the drug release from matrix tablets. Eur J. Pharm. Biopharm. 1998, 46(3):321-327.
96. Klausner E.A., Lavy E., Friedman M., Hoffman A. Expandable gastroretentive dosage forms. J. Controlled Release 2003, 90:143-162.
97. Streubel A., Siepmann J., Bodmeier R. Gastroretentive drug delivery systems. Expert Opinion on Drug Delivery 2006, 3(2):217-233.
98. Kagana L., Lapidotb N., Afarganb M., Kirmayerb D., Moora E., Mardorc Y., Friedmana M., Hoffman A. Gastroretentive accordion pill, enhancement of riboflavin bioavailability in humans. J. Controlled Release 2006, 113(3):208-215.
99. Pozzi F., Furlani P., Gazzaniga A., Davis S.S., Wilding I.R. The TIME CLOCK system, a new oral dosage form for fast and complete release of drug after a predetermined lag time. J. Controlled Release 1994, 3:99-108.
100. Ashford M., Fell J.T. Targeting drugs to the colon, delivery systems for oral administration. J. Drug Targeting 1994, 2:241-258.
101. Van den Mooter G. Colon drug delivery. Expert Opin Drug Deliv. 2006, 3(1):111-125. Jan.
102. Basit A.W. Advances in colonic drug delivery. Drugs 2005, 65(14):1991-2007.
103. Chourasia M.K., Jain S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Sci. 2003, 6(1):33-66.
104. Shareef M.A., Khar R.K., Ahuja A., Ahmad F.J., Raghava S. Colonic drug delivery, an updated review. AAPS PharmSci. 2003, 5(2):E17.
105. Maroni A., Zema L., Cerea M., Sangalli M.E. Oral pulsatile drug delivery systems. Expert Opinion on Drug Delivery 2005, 2(5):855-871.
106. Arora Shweta A.J., Ahuja A., Baboota Sanjula Q. Pulsatile drug delivery systems: An approach for controlled drug delivery. Indian J. Pharm. Sci. 2006, 68(3):95-300.
107. Till B., Ina O., Rolan B. Pulsatile drug-delivery systems. Critical reviews in therapeutic drug carrier systems 2001, 18(5):433-458.
108. Anal A.K. Time-controlled pulsatile delivery systems for bioactive compounds. Recent Patents on Drug Delivery & Formulation 2007, 1(1):73-77.
109. Eichel, H.J., Massmann, B.D. & Cobb, Jr., J.E. Delayed, sustained-release diltiazem pharmaceutical preparation. US Patent 5 529 790.
110. Hendrickson, D.L., Dimmitt, D.C., Williams, M.S., Skultety, P.F. & Baltezor, M.J. Diltiazem formulation. US Patent 5 286 497.
111. Barnwell, S.G. Biphasic release formations for lipophilic acids. US Patent 5 391 377.
112. Cheung W.K., Silber B.M., Yacobi A. Pharmacokinetic principles in the design of immediate-release components in sustained-release formulations with zero-order release characteristics. J. Pharm. Sci. 1991, 80(2):142-148.
113. Buttgereit F., Doering G., Schaeffler A., Witte S., Sierakowski S., Gromnica-Ihle E., Jeka S., Krueger K., Szechinski J., Alten R. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1), a double-blind, randomized controlled trial. Lancet 2008, 371:205-213.
114. Radebaugh, G.W., Murtha, J.L. & Glinecke, R. Oral sustained release acetaminophen formulation and process. US Patent 4 968 509.
115. Eichel, H.J. & Massmann, B.D. Sustained-release pharmaceutical preparation. US Patent 5 026 559.
116. Points to consider on the clinical requirements of modified release products submitted as a line extension of an existing marketing authorization. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal products (CPMP) December, 2003.
117. Mager D.E., Wyska E., Jusko W.J. Diversity of mechanism-based pharmacodynamic models. Drug Metab. Dis. 2003, 31(5):510-519.
118. Breimer D.D. An integrated pharmacokinetic and pharmacodynamic approach to controlled drug delivery. J. Drug Targetting 1996, 3:411-415.
119. Hoffman A. Pharmacodynamic aspects of sustained release preparations. Adv. Drug Delivery Rev. 1998, 33:185-199.
120. Sutton S.C. Companion animal physiology and dosage form performance. Advanced Drug Delivery Reviews 2004, 56(10):1383-1398.
121. Bauer K.H., Lehmann K., Osterwald H.P., Rothgang G Environmental Conditions in the Digestive Tract and their Influence on the Dosage Form. In: Coated Pharmaceutical Dosage Forms, Fundamentals, Manufacturing Techniques, Biophar-maceutical Aspects, Test Methods and Raw Materials 1998, 126-130. Medpharm GmbH Scientific Publishers, Birkenwaldstr, Stuttgart.
122. Abrahamssona B., Alpstenb M., Bakec B., Jonssona U.E., Eriksson-Lepkowskaa M., Larsson A. Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food. J. Controlled Release 1998, 52(3):301-310.
123. Qiu Y., Cheskin H., Engh K., Poska R. Once-a-day controlled-release dosage form of Divalproex Sodium I, formulation design and in vitro/in vivo investigations. J. Pharm. Sci. 2003, 92(6):1166-1173.
124. Vinks, A.A & Walson, P.D. (2003). Developmental Principles of Pharmacokinetics. Chapter 4. In: Pediatric Psychopharmacology, Principles and Practice. A. Martin, L. Scahill, D. S. Charney & J. F. Leckman (eds). Oxford University Press, New York, USA, p. 49.
125. Sutton S., Evans L., Fortner J., McCarthy J., Sweeney K. Dog colonoscopy model for predicting human colon absorption. Pharmaceutical Research 2006, 23(7):1554-1563.
126. Wilson C.G., Washington N. Gamma Scintigraphy in the Analysis of the Behaviors of Controlled Release Systems. Handbook of Pharmaceutical Controlled Release Technology 2000, 551-566. Marcel Dekker, Inc, New York, NY. D.L. Wise, A.M. Klibanov, R. Langer, A.G. Mikos, N.A. Peppas, D.J. Trantolo, G.E. Wnek, M.J. Yaszeski (Eds.).
127. Stevens H.N.E., Speakman M. Behaviour and transit of tamsulosin oral controlled absorption system in the gastrointestinal tract. Current Medical Research and Opinion 2006, 22(12):2323-2328.
128. Gualtieri, et al. Clinical studies of methylphenidate serum levels in children and adults. J. Am. Academy Child Psychiatry 1982, 21:19-26.
129. Pentikis H.S., Gonzalez M.A. Effect of formulation on methylphenidate release patterns: Clinical implications. Am. J. Drug Delivery 2005, 3(1):47-54.
130. Gonzalez M.A., Pentikis H.S., Anderl N., Benedict M.F., DeCory H.H., Dirksen S.J.H., Hatch S.J. Methylphenidate bioavailability from two extended-release formulations. Int. J. Clin. Pharmacol. Ther. 2002, 40:175-184.
131. Sonuga-Barke E.J.S., Van Lier P., Swanson J.M., Coghill D., Wigal S., Vandenberghe M., Hatch S. Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder: A growth mixture modeling analysis. Eur. Child Adolesc. Psychiatry 2007, Published online, 10 December.
132. Markowitz J.S., Straughn A.B., Patrick K.S., DeVane C.L., Pestreich L., Lee J., Wang Y., Muniz R. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin. Pharmacokinet. 2003, 42(4):393-401.
133. Wang Y., Lee L., Somma R., Thompson G., Bakhtiar R., Lee J., Rekhi G.S., Lau H., Sedek G., Hossain M. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Biopharm. Drug Dispos. 2004, 25(2):91-98.
134. Qiu, Y. (2002). Influence of drug properties and formulation design on in vivo performance of oral modified-release solid dosage forms. AAPS Conference on Pharmaceutics and Drug Delivery, Arlington, VA.
135. Qiu, Y. (2007). Design and evaluation of oral modified-release dosage forms based on drug property and delivery technology. Proceedings of CAE/AAPS/CPA/CRS/FIP/APSTJ Joint Conference, Oral Controlled Release Development and Technology. Shanghai, China. pp. 144-147.
136. Dmochowski R., Staskin D., Kell S. Oxybutynin chloride, alterations in drug delivery and improved therapeutic index. Expert Opinion on Pharmacotherapy 2002, 3(4):443-454.
137. Michel M.C. A benefit-risk assessment of extended-release oxybutynin. Drug Safety 2002, 25(12):867-876.
138. Dmochowski1 R.R., Staskin D.R. Advances in drug delivery: Improved bioavailability and drug effect. Current Urology Reports 2002, 3(6):1527-2737.